Analysis of antibody response in patients receiving recombinant Escherichia coli-derived human interferon-gamma.
Recombinant Escherichia coli-derived human interferon-gamma (rIFN-gamma) was given to a total of 20 patients by iv bolus injection at various doses once a week for 4 weeks. The sera obtained 7-10 days after the final injection were analyzed for antibodies against both rIFN-gamma and natural human IFN-gamma. Biological assays demonstrated that the postinoculation sera of the patients did not neutralize the antiviral activities of either rIFN-gamma or natural human IFN-gamma. Enzyme-linked immunosorbent assay showed that no detectable antibodies against rIFN-gamma were elicited. These results indicate that this rIFN-gamma preparation is not a potent antigen and may be suitable for longer-term clinical trials and applications in the future.
Liang
C M
CM
Herren
S
S
Fountoulakis
M
M
Otto
B
B
Hirschi
M
M
Gutzwiller
E
E
Gerlis
L
L
D000818:Animals; D000917:Antibody Formation; D001426:Bacterial Proteins / Q000276:immunology; D004269:DNA, Bacterial / Q000276:immunology; D004274:DNA, Recombinant; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology; D007371:Interferon-gamma / Q000276:immunology*; D007822:Laryngeal Neoplasms / Q000276:immunology; D008574:Mengovirus / Q000276:immunology; D011817:Rabbits / Q000276:immunology
D001426:Bacterial Proteins; D004269:DNA, Bacterial; D004274:DNA, Recombinant; D007371:Interferon-gamma